Advertisement
Screener

Inhibikase Therapeutics, Inc. (IKT) Net Margin

Inhibikase Therapeutics, Inc. (IKT) Net Margin

  • 2023-12-31: Net Margin -417794000.00%.
  • 2023-09-30: Net Margin -5775.11%.
  • 2023-06-30: Net Margin -4963.46%.
  • 2023-03-31: Net Margin -6940.03%.

Complete source-backed net margin history.

Available history
2020-03-31 to 2023-12-31
Data captured

Historical Net Margin

DateNet Margin
2023-12-31-417794000.00%
2023-09-30-5775.11%
2023-06-30-4963.46%
2023-03-31-6940.03%
2022-12-31-6731.67%
2022-09-30-61645.36%
2022-06-30-70817.14%
2022-03-31-10081.47%
2021-12-31-259342.54%
2021-09-30-1361.26%
2021-06-30-193.40%
2021-03-31-187.40%
2020-12-31-708.85%
2020-09-30-1779.72%
2020-06-30-192.12%
2020-03-31-202.17%

Annual Net Margin

DateNet Margin
2023-12-31-7304.73%
2022-12-31-14625.85%
2021-12-31-476.88%
2020-12-31-407.73%

Similar stocks

Stock NameCountryMarket CapPE Ratio
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
Liminatus Pharma, Inc. (LIMN)United States$0.282B
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Invivyd, Inc. (IVVD)United States$0.270B-2.42
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
Ocugen, Inc. (OCGN)United States$0.343B-6.34